The Effect of Lubricants on Viability of Bacillus Calmette-Guerin for Intravesical Immunotherapy Against Bladder Carcinoma
- 1 June 1996
- journal article
- Published by Wolters Kluwer Health in Journal of Urology
- Vol. 155 (6), 1892-1896
- https://doi.org/10.1016/s0022-5347(01)66040-3
Abstract
The viability of bacillus Calmette-Guerin (BCG) is crucial for induction of a local immune response and for effective therapy of recurrent superficial bladder carcinoma. During intravesical instillation of BCG lubricants are administered to assist catheterization, which contain bacteriostatic components that may interfere with the viability of mycobacteria. To verify this assumption, 5 commercially available lubricants were analyzed with regard to inhibition of viable BCG growth. Five different lubricants and their components were co-incubated with Connaught strain BCG and the resultant growth of BCG was assessed. To prove the significant passage of lubricants into the bladder, fluid was recovered from the bladder after catheterization, analyzed with regard to the bacteriostatic effect and compared to normal urine of different acidity. Significant impairment of BCG viability, dependent on dosage and time of co-incubation, was noted with all lubricants analyzed. Several components, namely lidocaine hydrochloride, glyceryl stearate, propyl-4-hydroxy-benzoate and chlorhexidine digluconate, were identified as responsible for this inhibition. Fluid recovered from the bladder after lubricant assisted catheterization also showed an inhibitory effect, indicating significant mixture of the instillate with lubricants. Generous use of lubricants to assist catheterization during intravesical BCG therapy will result in a clinically significant decrease in the number of intravesically instilled viable mycobacteria. For this reason, during intravesical immunotherapy with BCG only small amounts of lubricants should be used for urethral catheterization, and use of catheters not requiring lubricants should be considered.Keywords
This publication has 19 references indexed in Scilit:
- The induction of bacillus-Calmette-Guérin-activated killer cells requires the presence of monocytes and T-helper type-1 cellsCancer Immunology, Immunotherapy, 1995
- Dissecting the Immunobiological Effects of Bacillus Calmette-Guérin (BCG) In Vitro: Evidence of a Distinct BCG-Activated Killer (BAK) Cell PhenomenonJournal of Urology, 1993
- Intravesical BCG: Current results, natural history and implicants for urothelial cancer preventionJournal of Cellular Biochemistry, 1992
- A Randomized Trial of Intravesical Doxorubicin and Immunotherapy with Bacille Calmette–Guérin for Transitional-Cell Carcinoma of the BladderNew England Journal of Medicine, 1991
- Fibronectin-mediated Calmette-Guerin bacillus attachment to murine bladder mucosa. Requirement for the expression of an antitumor response.JCI Insight, 1990
- HLA—DR Expression by High Grade Superficial Bladder Cancer Treated with BCGBritish Journal of Urology, 1989
- Inhibition of murine bladder tumor growth by bacille Calmette-Guerin: Lack of a role of natural killer cellsClinical Immunology and Immunopathology, 1986
- SYSTEMIC COMPLICATIONS OF INTRAVESICAL BCG THERAPY FOR BLADDER CANCERThe Lancet, 1985
- Immunotherapy of Murine Transitional Cell CarcinomaJournal of Urology, 1982
- Histopathology of Tumor Regression After Intralesional Injection of Mycobacferium bovis . IV. Development of Immunity to Tumor Cells and BCG 2JNCI Journal of the National Cancer Institute, 1973